Featured Courses

Final Chapter: Post-COVID-19 Fibrosis and the Role of Antifibrotic Therapy Management | myCME

AMA PRA Category 1 Credit(s)^TM

What do we know about post-ARDS fibrosis in patients who have recovered from COVID-19? In this 10-minute CME-certified vlog, leading pulmonology expert Christopher King, MD, FACP, FCCP, Director of Transplant and Advanced Lung Disease Critical Care Program at Inova Fairfax Hospital, will discuss topics such as post-ARDS fibrosis in patients who have recovered from COVID-19, the potential role of antifibrotic therapies, ongoing clinical trials

The Next Chapter: Post-Care After COVID-19 Recovery | myCME

AMA PRA Category 1 Credit(s)^TM

In this concise 15-minute CME-certified vlog, hear from leading Pulmonology expert, Imre Noth, MD, Chief of Pulmonary & Critical Care Medicine from the University of Virginia School of Medicine who will discuss long-term post-COVID-19 monitoring strategies.

Straight Talk with the Expert Surrounding COVID-19 and Your Patients with ILD | myCME

AMA PRA Category 1 Credit(s)^TM

Dr. Imre Noth summarizes what we have learned through August 2020 about COVID-19 and its implications for patients with interstitial lung disease (ILD) while providing his own front-line clinical experiences. Talking points include mitigating risks of COVID-19 in patients with ILD, strategies to help patients continue ILD treatment and supportive care, as well as strategies to differentiate post-ARDS fibrosis and ILDs.

Prevention and Treatment of Recurrent Clostridioides difficile Infection | myCME

AMA PRA Category 1 Credit(s)^TM

This 1-hour interprofessional educational activity reviews the epidemiology of recurrent C. difficile infection, current and emerging pharmacologic and non-pharmacologic therapies, and special populations at risk for infection.

COVID-19 Virtual Panel | myCME

AMA PRA Category 1 Credit(s)^TM

This panel discussion features a pulmonologist, radiologist, and infectious disease specialist, who discuss management and treatment for COVID-19 patients that develop acute lung injury or acute respiratory distress syndrome (ARDS). The discussion synthesizes current data, protocols, and management strategies for caring for COVID-19 patients as well as post discharge monitoring.

Streamlining the Journey to a Cure: Optimizing the Hepatitis C Virus Care Cascade | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

This CME Outfitters live and on-demand webcast will feature expert faculty hosting an interactive discussion on implementing HCV screening, developing new methods of coordinated care, and addressing barriers to treatment access.

Pull the Levers That You Can: Managing HIV in an Aging Population | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

In this CME Outfitters BriefCase, expert faculty will present a patient case focusing on the impact of comorbidities and how to individualize treatment regimens for aging patients with HIV, based on their specific needs and comorbidities.

HIV Prevention in Primary Care Practice: A PrEP Primer (An HIV Prevention eHealth Source™) | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

Preexposure prophylaxis (PrEP) is a broad set of clinical tools that can be used to reduce the chances of acquiring human immunodeficiency virus (HIV). Although it is highly effective, many people who could benefit from PrEP lack access or are not familiar with it.

HCV in People Who Inject Drugs: A Call to Action for Frontline Providers | myCME

AMA PRA Category 1 Credit(s)^TM

In this activity, expert faculty will describe the epidemiologic imperative for HCV treatment as prevention within populations of people who inject drugs (PWID). The participant will learn both the importance of and tactics for HCV testing and linkage to HCV treatment. Barriers to treatment of HCV-positive PWID and outdated clinical assumptions regarding eligibility and prescribing limitations will be discussed, along with current clinical evidence for the feasibility and success of treatment.

Addressing the Real-World Challenge of HCV Cure in People Who Inject Drugs: Opportunities for Current and New HCV Treaters | myCME

AMA PRA Category 1 Credit(s)^TM

In this activity, expert faculty will present the epidemiologic imperative for HCV treatment as prevention within populations of people who inject drugs (PWID). Potential barriers to treatment of HCV-positive PWID, including outdated clinical assumptions regarding treatment eligibility and prescribing limitations, will be discussed.

Starting PrEP in a 19-Year-Old African American Man With an STI | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), AAPA Category I CME credit

The second part of a myCME Case Clinic series features a young patient who was recently treated for a sexually transmitted infection by his PCP.

When is Switching ART Necessary? | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

In this CME Outfitters BriefCase, faculty will highlight a patient case that focuses on seizing opportunities to optimize and simplify treatment for patients with human immunodeficiency virus (HIV) while maintaining virologic suppression, as well as best practices for engaging patients in shared decision-making so that patient preference is always considered.